Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Open-Label Study to Compare Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Men and Women

NCT02218320 is registered in ClinicalTrials.gov with University of North Carolina, Chapel Hill as lead sponsor.

NCT NCT02218320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02218320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Open-Label Study to Compare Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Men and Women
Lead sponsor
University of North Carolina, Chapel Hill
Phase
Observational
Overall status
Completed
Start date
October 31, 2014
Completion date
October 31, 2015
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus